Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic resistance to anti-oestrogen therapy in breast cancer
Marie Will, Jackson Liang, Ciara Metcalfe, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 10, pp. 673-685
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions
Rohan Kalyan Rej, Joyeeta Roy, Srinivasa Rao Allu
Cancers (2024) Vol. 16, Iss. 3, pp. 552-552
Open Access | Times Cited: 18
Circulating tumor DNA validity and potential uses in metastatic breast cancer
Ottavia Amato, Nefeli Giannopoulou, Michail Ignatiadis
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 16
Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors
Zhengyan Kan, Ji Wen, Vinícius Bonato, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance
Wen Li, Xiaoxian Shi, C. S. Tan, et al.
Nature Chemical Biology (2025)
Closed Access | Times Cited: 2
Targeting systemic and gut microbial metabolism in ER+ breast cancer
Hannah Heath, Ayca Nazli Mogol, Ashlie Santaliz Casiano, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 4, pp. 321-330
Closed Access | Times Cited: 6
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
Konstantinos Venetis, Francesco Pepe, Carlo Pescia, et al.
Cancer Treatment Reviews (2023) Vol. 121, pp. 102642-102642
Closed Access | Times Cited: 14
Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer
Eneda Toska
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189097-189097
Open Access | Times Cited: 5
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
Rei Kudo, Anton Safonov, Catherine Jones, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1919-1935.e9
Open Access | Times Cited: 5
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences
Roberta Scafetta, Paola Zagami, Marzia Del Re, et al.
Breast Cancer Research and Treatment (2025)
Closed Access
ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer
Jackson Liang, Xiaosai Yao, Patrick Aouad, et al.
Nature Cancer (2025)
Closed Access
Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy
Sacha J. Howell, Sacha J. Howell
Advances in experimental medicine and biology (2025), pp. 449-474
Closed Access
An on‐Demand Oxygen Nano‐vehicle Sensitizing Protein and Nucleic Acid Drug Augment Immunotherapy
Zhang Sidi, Xinghui Wang, Xiaojing Chen, et al.
Advanced Materials (2025)
Closed Access
LncRNA TCL6 regulates miR-876–5p/MYL2 axis to suppress breast cancer progression
Yaobang Liu, Haipeng Li, Dahai Chai, et al.
Translational Oncology (2025) Vol. 53, pp. 102210-102210
Closed Access
A circRNA–mRNA pairing mechanism regulates tumor growth and endocrine therapy resistance in ER-positive breast cancer
Yi Jia, Jiao Du, Xue Chen, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 8
Open Access
Exposing the cellular situation: findings from single cell RNA sequencing in breast cancer
Gaofeng Ni, Xinhan Li, Wenyang Nie, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
The Role of Yes‐Associated Protein in Inflammatory Diseases and Cancer
Bing Zhong, Jintao Du, Feng Liu, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access
SCN3B is an Anti-breast Cancer Molecule with Migration Inhibition Effect
Yinfeng Zhao, Jianzhong Ye, Yun Liang, et al.
Biochemical Genetics (2025)
Closed Access
Ultrasound-actuated Ion Homeostasis Perturbator for Oxidative Damage-augmented Ca2+ Interference Therapy and Combined Immunotherapy
Mi Yang, Yaqin Hu, Xiuxiu Hao, et al.
Materials Today Bio (2025), pp. 101666-101666
Open Access
Oral selective estrogen receptor degraders (SERDs) in Hormone receptor-Positive HER2-Negative Metastatic breast cancer After Progression with CDK4/6 inhibitors
Taha Koray Şahin, Sercan Aksoy, Deniz Can Güven
Expert Review of Anticancer Therapy (2025)
Closed Access
Bioorthogonal SERS-Bioluminescence Dual-Modal Imaging for Real-Time Tracking of Triple-Negative Breast Cancer Metastasis
Wei Zhang, Sisi Wang, Yanlong Xing, et al.
Acta Biomaterialia (2025)
Closed Access
Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations
Yasuaki Uemoto, Chang-Ching Lin, Bingnan Wang, et al.
Cancer Letters (2025), pp. 217668-217668
Closed Access
The role of ferroptosis in breast cancer: tumor progression, immune microenvironment interactions and therapeutic interventions
Yiping Wang, Chuanyun Tang, Keqin Wang, et al.
European Journal of Pharmacology (2025) Vol. 996, pp. 177561-177561
Closed Access
Silk fibroin: An innovative protein macromolecule-based hydrogel/scaffold revolutionizing breast cancer treatment and diagnosis – Mechanisms, advancements, and targeting capabilities
Shubhrajit Mantry, Kotaiah Silakabattini, Prabhat Kumar Das, et al.
International Journal of Biological Macromolecules (2025), pp. 142870-142870
Closed Access
Metastasiertes hormonrezeptorpositives Mammakarzinom – die Qual der Wahl
Marion van Mackelenbergh, Michael Friedrich, Nicolai Maass
Die Gynäkologie (2025)
Closed Access
APOBEC3 mutagenesis drives therapy resistance in breast cancer
Avantika Gupta, Andrea Gazzo, Pier Selenica, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top